A pilot study on the effect of apomorphine on visual perception in patients with Parkinson's disease and visual hallucinations

A pilot study on the effect of apomorphine on visual perception in patients with Parkinson's disease and visual hallucinations - Apomorphine and visual hallucinations in Parkinson's disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31583

Enrollment

Registered

2008-11-24

Start date

2019-07-23

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypokinetic rigid syndrome Parkinson's disease

Interventions

The application of apomorphine via a subcutaneous infusion during three hours.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed Parkinson*s Disease according to the UK Brain Bank Criteria 2. Al least weekly hallucinations during the past month 3. MMSE >24 4. FAB>=12 5. Patient must be able to understand the procedure 6. Medication must be stable for at least a month

Exclusion criteria

Exclusion criteria: 1. Visual problems (cataract, macula degeneration, severe retinal patholgy, visus

Design outcomes

Primary

Measure	Time frame
The change in prestation on the VOSP related to the presence or absence of the apomorphine infusion.	—

Secondary

Measure	Time frame
1. Lower order visual perception tests consisting of Mars Letter Contrast Sensitivity Test, Visual field measurement, Primary vision measurement, Color differentiation, Visual overview and perceptual speed (TAVTMB). 2. Cognitive and attentional tests consisting of reactiontime (Schuhfried S7), Frontal Lobe assessment Battery (FAB) and the SCOPA-Cog 3. Motor function test consisting of the SPES/ SCOPA.	—

Measure

Time frame

1. Lower order visual perception tests consisting of Mars Letter Contrast Sensitivity Test, Visual field measurement, Primary vision measurement, Color differentiation, Visual overview and perceptual speed (TAVTMB). 2. Cognitive and attentional tests consisting of reactiontime (Schuhfried S7), Frontal Lobe assessment Battery (FAB) and the SCOPA-Cog 3. Motor function test consisting of the SPES/ SCOPA.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)